{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T12:03:20Z","timestamp":1794830600340,"version":"4.9.1"},"reference-count":140,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["1053344"],"award-info":[{"award-number":["1053344"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","award":["AO 2-2015"],"award-info":[{"award-number":["AO 2-2015"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Ministry of Health","award":["RF 2010-2317822"],"award-info":[{"award-number":["RF 2010-2317822"]}]},{"name":"CARIPLO","award":["2011-0644"],"award-info":[{"award-number":["2011-0644"]}]}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jhep.2016.05.043","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T20:23:34Z","timestamp":1464985414000},"page":"835-848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Aiming for cure in HBV and HDV infection"],"prefix":"10.1016","volume":"65","author":[{"given":"J\u00f6rg","family":"Petersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Levrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.05.043_b0005","first-page":"88","article-title":"Latest developments in the treatment of Hepatitis B","volume":"62","author":"Dandri","year":"2016","journal-title":"Minerva Gastroenterol Dietol"},{"key":"10.1016\/j.jhep.2016.05.043_b0010","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1136\/gutjnl-2012-302056","article-title":"New insight in the pathobiology of hepatitis B virus infection","volume":"61","author":"Dandri","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.05.043_b0015","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrgastro.2009.160","article-title":"Hepatitis: Monitoring drug therapy for hepatitis B\u2014a global challenge?","volume":"6","author":"Nguyen","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0020","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.043_b0025","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2005.03.009","article-title":"Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy","volume":"128","author":"Sung","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.043_b0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/135965350601100704","article-title":"One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels","volume":"11","author":"Wong","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.05.043_b0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350801300106","article-title":"Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication","volume":"13","author":"Lutgehetmann","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.05.043_b0040","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0045","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.043_b0055","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/gutjnl-2014-307023","article-title":"Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians","volume":"64","author":"Arends","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.05.043_b0060","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/liv.12720","article-title":"Optimal therapy for chronic hepatitis B: Hepatitis B combination therapy?","volume":"35","author":"Petersen","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.05.043_b0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of Hepatitis B surface antigen in patients with chronic Hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.043_b0070","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/hep.27586","article-title":"Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study)","volume":"61","author":"Brouwer","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0075","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/cid\/ciu702","article-title":"A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B \u201ce\u201d antigen-positive chronic hepatitis B","volume":"59","author":"Xie","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.05.043_b0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhep.2014.08.021","article-title":"Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy","volume":"62","author":"Marcellin","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0085","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomized open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/liv.13018","article-title":"The adventure of delta","author":"Rizzetto","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.05.043_b0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0105","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2011.09.018","article-title":"Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study","volume":"56","author":"Petersen","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0110","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1016\/S0168-8278(14)61249-6","article-title":"Add-on therapy with entecavir plus tenofovir due to viral resistance or partial responses followed by monotherapy in CHB patients: final results from an international multicenter study","volume":"60","author":"Petersen","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0115","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0120","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.043_b0125","article-title":"Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP)","volume":"10","author":"Veloso","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.05.043_b0130","unstructured":"Watashi K, Tsukusa S, Shimura S, Kaneko M, Sluder A, Peel M et al. Identification of NTCP-targeting small molecules that inhibit HBV entry by cell-based and in vitro-technologies. 2015 International meeting on molecular biology of hepatitis B viruses, Bad Nauheim, Germany, October 4\u20138, 2015, Abstract O-7 (personal communication)."},{"key":"10.1016\/j.jhep.2016.05.043_b0135","unstructured":"Tsukuda S, Watashi K, Iwamoto M, Suzuki R, Aizaki H, Tsukusa S et al. Clinipidine inhibits the early phase of HBV infection in a NTCP independent mechanism. 2015 International meeting on molecular biology of hepatitis B viruses, Bad Nauheim, Germany, October 4\u20138, 2015, Abstract O-200 (personal communication)."},{"key":"10.1016\/j.jhep.2016.05.043_b0140","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2016.05.043_b0145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"Lutgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0150","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B \u2013 first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2016.03.031","article-title":"A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B","author":"Uhl","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.jhep.2016.05.043_b0160","unstructured":"Xinfeng H, Fengfeng M, Zhiyi J, Xiaohui L, Wenhui L. Inactivation of NTCP causes gallbladder disease in mice. 2015 International meeting on molecular biology of hepatitis B viruses, Bad Nauheim, Germany, October 4\u20138, 2015, Abstract O-177 (personal communication)."},{"key":"10.1016\/j.jhep.2016.05.043_b0165","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/S0168-8278(16)00073-8","article-title":"Combination of the hepatitis B\/D entry inhibitor Myrcludex B and tenofovir: assessment of the effect on plasma bile acid profiles and tenofovir pharmacokinetics","volume":"64","author":"Blank","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0170","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","article-title":"First-in-human application of the first-in-class hepatitis B and Hepatitis D virus entry inhibitor myrcludex B","volume":"65","author":"Blank","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.28013","article-title":"A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses","volume":"63","author":"Verrier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0180","doi-asserted-by":"crossref","first-page":"E4244","DOI":"10.1073\/pnas.1409986111","article-title":"Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses","volume":"111","author":"Koniger","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.05.043_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128401","article-title":"Does Tyrosyl DNA Phosphodiesterase-2 Play a Role in Hepatitis B Virus Genome Repair","volume":"10","author":"Cui","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.05.043_b0190","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.05.043_b0195","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0200","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.gastro.2006.01.001","article-title":"Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones","volume":"130","author":"Pollicino","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.043_b0205","doi-asserted-by":"crossref","first-page":"19975","DOI":"10.1073\/pnas.0908365106","article-title":"Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function","volume":"106","author":"Belloni","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.05.043_b0210","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2011.02.015","article-title":"Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection","volume":"55","author":"Lucifora","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0215","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2015.06.023","article-title":"HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase","volume":"63","author":"Rivi\u00e8re","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0220","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2016.05.043_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003613","article-title":"Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes","volume":"9","author":"Liu","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2016.05.043_b0230","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/S0168-8278(15)30134-3","article-title":"High antiviral activity of the HBV core inhibitor NVR 3\u2013778 in the humanized uPA\/SCID mouse model","volume":"62","author":"Klumpp","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0235","first-page":"309A","article-title":"Silencing HBV transcription by targeting cccDNA-bound chromatin modifiers","volume":"60","author":"Palumbo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0240","doi-asserted-by":"crossref","first-page":"E5715","DOI":"10.1073\/pnas.1518090112","article-title":"Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation","volume":"112","author":"Tropberger","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.05.043_b0245","doi-asserted-by":"crossref","first-page":"S513","DOI":"10.1016\/S0168-8278(15)30737-6","article-title":"Capsid drugs HAP12 and AT130 target HBV core protein nuclear functions","volume":"62","author":"Belloni","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0250","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/JVI.02574-12","article-title":"Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription","volume":"87","author":"Benhenda","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2016.05.043_b0255","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","article-title":"Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor","volume":"531","author":"Decorsiere","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2016.05.043_b0260","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: A pleiotropic keystone in the HBV lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2016.05.043_b0265","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jhep.2016.05.043_b0270","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-\u03b3 and tumor necrosis factor-\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.043_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097579","article-title":"AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.05.043_b0280","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2016.05.043_b0285","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.antiviral.2015.10.004","article-title":"Targeting hepatitis B virus cccDNA using CRISPR\/Cas9","volume":"123","author":"Kennedy","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2016.05.043_b0290","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","article-title":"Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR\/Cas RNA-guided DNA endonuclease","volume":"476","author":"Kennedy","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2016.05.043_b0295","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus","volume":"2","author":"Ramanan","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2016.05.043_b0300","article-title":"Targeting Hepatitis B virus with CRISPR\/Cas9","volume":"16","author":"Seeger","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jhep.2016.05.043_b0305","article-title":"The CRISPR\/ Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo","volume":"3","author":"Wang","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jhep.2016.05.043_b0310","first-page":"276A","article-title":"The nuclear function of Hepatitis B capsid (HBc) protein is to inhibit IFN response very early after infection of hepatocytes","volume":"58","author":"Gruffaz","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0315","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","article-title":"Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro","volume":"46","author":"Delaney","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.05.043_b0320","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2007.06.014","article-title":"The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging","volume":"76","author":"Feld","year":"2007","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2016.05.043_b0325","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/cb100275b","article-title":"Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators","volume":"5","author":"Katen","year":"2010","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jhep.2016.05.043_b0330","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jhep.2016.05.043_b0335","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1073\/pnas.0409732102","article-title":"A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly","volume":"102","author":"Stray","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.05.043_b0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025096","article-title":"Antiviral activity of Bay 41\u20134109 on hepatitis B virus in humanized Alb-uPA\/SCID mice","volume":"6","author":"Brezillon","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.05.043_b0345","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3851\/IMP2152","article-title":"In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations","volume":"17","author":"Wang","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.05.043_b0350","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/rcm.6710","article-title":"Characterization of metabolites of GLS4 in humans using ultrahigh-performance liquid chromatography\/quadrupole time-of-flight mass spectrometry","volume":"27","author":"Zhou","year":"2013","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.jhep.2016.05.043_b0355","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.antiviral.2011.08.012","article-title":"The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication","volume":"92","author":"Billioud","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2016.05.043_b0360","first-page":"223A","article-title":"Inhibition of Hepatitis B Virus Replication by the HBV Core Inhibitor NVR 3\u2013778","volume":"62","author":"Lam","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0365","first-page":"LB-19","article-title":"Phase 1a safety and pharmacokinetics of NVR 3\u2013778, a potential first-in-class HBV core inhibitor","volume":"60","author":"Gane","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0370","first-page":"1385A","article-title":"Phase 1b efficacy and safety of NVR 3\u2013778, a first-in-class HBV core inhibitor, in HBeAg-positive patients with chronic HBV infection","volume":"62","author":"Yuen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0375","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/S0168-8278(16)00175-6","article-title":"NVR 3\u2013778, a first in class core inhibitor, alone and in combination with PEG-Interferon (PEGIFN), in treatment na\u00efve HBeAg-positive patients: early reductions in HBV DNA and HBeAg","volume":"64","author":"Yuen","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0380","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1073\/pnas.91.6.2235","article-title":"Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin","volume":"91","author":"Block","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.05.043_b0385","first-page":"125","article-title":"Glucosidase inhibitors as antiviral agents for hepatitis B and C","volume":"8","author":"Durantel","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.jhep.2016.05.043_b0390","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1021\/jm200696v","article-title":"Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion","volume":"54","author":"Yu","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhep.2016.05.043_b0395","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2014.04.002","article-title":"Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion","volume":"107","author":"Xu","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2016.05.043_b0400","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1128\/AAC.01003-13","article-title":"Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.05.043_b0405","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1128\/AAC.01005-13","article-title":"Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.05.043_b0410","first-page":"478A","article-title":"REP 9 AC: a potent HBsAg release inhibitor that elicits durable immunological control of chronic HBV infection","volume":"54","author":"Mahtab","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0415","first-page":"64A","article-title":"Nucleic acid polymers REP 9 AC\/REP 9 AC\u2019 elicit sustained immunologic control of chronic HBV infection","volume":"7","author":"Mahtab","year":"2011","journal-title":"Glob Antiviral J"},{"key":"10.1016\/j.jhep.2016.05.043_b0420","unstructured":"Mahtab MA, Bazinet M, Vaillant A. REP 2055\/REP 2139-Ca Asian Clinical data update. Lancet hepatitis summit 2015, Shanghai April 10\u201312, China."},{"key":"10.1016\/j.jhep.2016.05.043_b0425","doi-asserted-by":"crossref","first-page":"S584","DOI":"10.1016\/S0168-8278(16)01073-4","article-title":"Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in chronic HBV\/HDV co-infection in Caucasian patients","volume":"64","author":"Bazinet","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0430","unstructured":"Brikh C, Jamard C, Quinet J, Bouchareb C. Modifications of nucleic acid polymers decrease liver accumulation without affecting antiviral activity against HBV. 2015 International meeting on molecular biology of hepatitis B viruses, Bad Nauheim, Germany, October 4\u20138, 2015, Abstract P-239 (personal communication)."},{"key":"10.1016\/j.jhep.2016.05.043_b0435","unstructured":"Quinet P, Jamard C, Vaillant A, Cova L. Combination therapy with the nucleic acid polymer REP 2139-Ca and nucleos(t)ide analogues improves antiviral responses against hepatitis B in vivo. HepDart 2015, Grand Wailea, Hawaii, December 6\u201310, 2015."},{"key":"10.1016\/j.jhep.2016.05.043_b0440","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virusres.2004.01.011","article-title":"Interfering with hepatitis C virus RNA replication","volume":"102","author":"Randall","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.jhep.2016.05.043_b0445","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role for a bidentate ribonuclease in the initiation step of RNA interference","volume":"409","author":"Bernstein","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2016.05.043_b0450","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/35005107","article-title":"An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells","volume":"404","author":"Hammond","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2016.05.043_b0455","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2016.05.043_b0460","first-page":"707A","article-title":"ARC-520 RNAi therapeutic reduces HBV DNA, s and e antigen in a chimpanzee with a very high biral titer","volume":"58","author":"Lanford","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0465","first-page":"LB21","article-title":"Phase II, dose-ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection","volume":"60","author":"Yuen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0470","first-page":"2022A","article-title":"Monthly dosing of ARC-520 in chronically hepatitis B virus infected chimpanzees produces rapid, deep and durable reductions in circulating viral antigens","volume":"62","author":"Wooddell","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0475","first-page":"LB-9","article-title":"ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B","volume":"62","author":"Yuen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0480","unstructured":"MacLachlan I, editor. Update on the preclinical development of an LNP-based HBV therapeutic. 10th annual meeting of the oligonucleotide therapeutics society; 2014; San Diego, California, USA."},{"key":"10.1016\/j.jhep.2016.05.043_b0485","first-page":"222A","article-title":"Goetzmann3, Guerra B, al. e. Reductions in cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic hepatitis B virus infection implicate integrated DNA in maintaining circulating HBsAg","volume":"62","author":"Wooddell","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0490","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2014.10.004","article-title":"Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production","volume":"148","author":"Phillips","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.043_b0495","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1016\/S0168-8278(14)61204-6","article-title":"NVP018, a cyclophilin inhibitor for treatment of chronic HBV infection","volume":"60","author":"Nilsson","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0500","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.1128\/JVI.76.20.10465-10472.2002","article-title":"A prenylation inhibitor prevents production of infectious hepatitis delta virus particles","volume":"76","author":"Bordier","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2016.05.043_b0505","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1172\/JCI17704","article-title":"In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus","volume":"112","author":"Bordier","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2016.05.043_b0510","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2016.05.043_b0515","doi-asserted-by":"crossref","first-page":"S587","DOI":"10.1016\/S0168-8278(16)01079-5","article-title":"Hepatitis delta virus kinetics under the prenylation inhibitor lonafarnib suggest HDV-mediated suppression of HBV replication","volume":"64","author":"Yurdaydin","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0520","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.icb.7100100","article-title":"Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response","volume":"85","author":"Thompson","year":"2007","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jhep.2016.05.043_b0525","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/jvh.12174","article-title":"Long-term stimulation of Toll-like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses induced by poly I: C treatment","volume":"21","author":"Broering","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.05.043_b0530","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/jvh.12216","article-title":"Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen","volume":"21","author":"Jiang","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.05.043_b0535","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2012.05.004","article-title":"Role of Toll-like receptor 2 in the immune response against hepadnaviral infection","volume":"57","author":"Zhang","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0540","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.22751","article-title":"Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells","volume":"49","author":"Wu","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0545","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.21897","article-title":"Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice","volume":"46","author":"Wu","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0550","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3851\/IMP1294","article-title":"Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro","volume":"14","author":"Thompson","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.05.043_b0555","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/gutjnl-2014-308211","article-title":"Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B","volume":"64","author":"Giles","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.05.043_b0560","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/hep.21482","article-title":"Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein","volume":"45","author":"Visvanathan","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026315","article-title":"Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells","volume":"6","author":"Vincent","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.05.043_b0570","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.043_b0575","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0580","first-page":"1187A","article-title":"Functional activation of NK and CD8+ T cells in vitro by the toll-like receptor 7 agonist GS-9620","volume":"62","author":"Steuer","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0585","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2014.12.016","article-title":"The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus","volume":"42","author":"Sato","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2016.05.043_b0590","doi-asserted-by":"crossref","first-page":"S557","DOI":"10.1016\/S0168-8278(15)30841-2","article-title":"Antiviral efficacy and induction of host immune responses with SB 9200, an oral prodrug of the dinucleotide SB 9000, in the woodchuck model of chronic hepatitis B virus (HBV) infection","volume":"62","author":"Korolowicz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0595","doi-asserted-by":"crossref","first-page":"S602","DOI":"10.1016\/S0168-8278(16)01111-9","article-title":"Antiviral efficacy and host immune response induction with SB9200, an oral prodrug of the dinucleotide SB9000, in combination with entecavir in the woodchuck model of chronic hepatitis B","volume":"64","author":"Korolowicz","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0600","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1016\/S0168-8278(15)30194-X","article-title":"SB 9200, a novel immunomodulator for patients with viral hepatitis: Phase 1 mad study in patients with hepatitis c virus (HCV) infection","volume":"62","author":"Thompson","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0605","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2016.05.043_b0610","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/hep.23936","article-title":"The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function","volume":"52","author":"Raziorrouh","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0615","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2016.05.043_b0620","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.043_b0625","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047648","article-title":"Upregulation of the Tim-3\/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection","volume":"7","author":"Nebbia","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.05.043_b0630","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.24249","article-title":"Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection","volume":"53","author":"Schurich","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001227","article-title":"Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection","volume":"6","author":"Peppa","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2016.05.043_b0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.05.043_b0645","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.tps3111","article-title":"Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis","volume":"31","author":"Sangro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.05.043_b0650","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1073\/pnas.1502400112","article-title":"Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis","volume":"112","author":"Ebert","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.05.043_b0655","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1502390112","article-title":"Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus","volume":"112","author":"Ebert","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.05.043_b0660","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","article-title":"Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study","volume":"32","author":"Gaggar","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2016.05.043_b0665","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","article-title":"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice","volume":"64","author":"Martin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.05.043_b0670","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/cgt.2013.65","article-title":"DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques","volume":"20","author":"Obeng-Adjei","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jhep.2016.05.043_b0675","first-page":"1191A","article-title":"Safety and efficacy of GS-4774 in patients with chronic hepatitis B on oral antiviral therapy","volume":"62","author":"Lok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.043_b0680","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/S0168-8278(16)00039-8","article-title":"RNA interference mediated suppression of HBV transcripts restores HBV-specific immunity and enhances the efficacy of therapeutic vaccination","volume":"64","author":"Michler","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0685","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/S0168-8278(15)30005-2","article-title":"Engineered HBV-specific T cells: Disentangling antiviral from killing capacity","volume":"62","author":"Koh","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0690","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.05.043_b0695","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","article-title":"Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines","volume":"55","author":"Gehring","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.043_b0700","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/S0168-8278(16)00045-3","article-title":"Immunotherapy using T cells redirected against HBV results in reduced viral loads and enhanced immune responses in humanized mice","volume":"64","author":"Kah","year":"2016","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816302574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816302574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T02:01:58Z","timestamp":1656640918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816302574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":140,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0168827816302574"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.05.043","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aiming for cure in HBV and HDV infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.05.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}